| LBCTR2019090238 | SHP647-302 | A study of the Efficacy and Safety of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects with Moderate to Severe Ulcerative Colitis | Interventional | Other | 27/05/2019 |
| LBCTR2019090265 | SHP647-307 | A study on the Efficacy and Safety of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) | A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Maintenance Therapy in Subjects With Moderate to Severe Crohn’s Disease (CARMEN CD 307) | Interventional | Other | 07/01/2020 |
| LBCTR2023075332 | ACE-536-MF-002 | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE) | A phase 3, double-blind, randomized study to compare the efficacy and safety of Luspatercept (ACE-536) versus placebo in subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis on concomitant JAK2 inhibitor therapy and who require red blood cell transfusions | Interventional | Recruiting | 13/04/2023 |
| LBCTR2022014844 | AG348-C-017 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT) | A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Non–Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE) | Interventional | Pending | 15/07/2021 |
| LBCTR2022014845 | AG348-C-018 | A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT) (ENERGIZE-T). | A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T) | Interventional | Pending | 15/07/2021 |
| LBCTR2019080217 | GBT440-031 | Study to Evaluate the Effect of Voxelotor Administered Orally to Patients With Sickle Cell Disease (GBT_HOPE) | A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study of Voxelotor Administered Orally to Patients With Sickle Cell Disease | Interventional | Complete | 16/07/2020 |
| LBCTR2019010185 | CABL001A2301 | A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors | A Phase 3, Multi-center, Open-label, Randomized Study of Oral ABL001 Versus Bosutinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors | Interventional | Complete | 22/01/2019 |
| LBCTR2024015495 | 1517-CL-1003 | A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease | A Phase 3, Open-label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Treatment of Anemia in Pediatric Participants with Chronic Kidney Disease | Interventional | Pending | 05/01/2024 |
| LBCTR2020043427 | APD334-302 | Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | Interventional | Complete | 08/03/2020 |
| LBCTR2020043405 | APD334-301 | Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis | A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis | Interventional | Complete | 25/02/2020 |